(ACAD) Acadia Pharma filed to sell up to $100M in securities.
(AGU) Agrium noted positively on Cramer’s MAD MONEY.
(AMGN) Amgen released positive phase II Aranesp data for treating anemia in cancer patients.
(ARDI) @Road being acquired by TRMB for $7.50 per share in a $496 million deal.
(AVRX) Avalon Pharma shoed positive preliminary results in cancer studies.
(BCRX) BioCryst Pharma proceeding to Phase II studies of Fodosine in patients with advanced refractory CTCL.
(BEC) Beckman Coulter filed to sell $500M in notes and will repurchase up to 2.5M shares.
(BGF) B&G Foods filed to sell $200M in securities.
(BMET) Biomet bids are reportedly coming from SNN by tomorrow; stock up 5% at $42.00+..
(C) Citigroup reportedly buying Egg Internet’s banking arm from Prudential PLC in UK.
(CPHD) Cepheid receive marketing approval from the FDA for its GBS test.
(DD) DuPont indicated a tad higher as it raised EPS guidance on items, announced tax update, and announced 1500 global layoffs in restructuring.
(DLP) Delta Pine’s acquisition from Monsanto may have a snag according to WSJ.
(ELX) Emulex cut to Neutral at B of A.
(F) Ford is reportedly selling its Aston Martin unit to a Syrian billionaire.
(GERN) Geron’s Telomerase cancer drug active against stem cells.
(GHS) Gatehouse Media noted as overvalued in barron’s.
(HAIN) Hain Celestial acquired private Haldane Foods.
(HD) Home Depot is paying $100M for a stake in China’s HomeWay.
(HET) Harrah’s board is meeting to consider bids this week according to WSJ.
(HIG) Hartford Insurance reiterated guidance.
(LPL) LG Philips LCD had offices raised in antitrust probe.
(MLNM) Millenium Pharma positive results on Velcade in new studies.
(MOS) Mosaic noted positively on Cramer’s MAD MONEY.
(NT) NorTel noted as in midst of successful turnaround at Barron’s.
(PSO) Pearson agreed to sell 90 percent of its Pearson Government Solutions division to New York private equity Veritas Capital for about $600M.
(SYNT) Syntel filed to sell 3M shares of common stock for share holders.
(TARO) Taro Pharma trading up 12% on reports out of Israel that it is in acquisition talks.
(TSG) Sabre Group could be sold this week according to WSJ.
(TXN) Texas Inst. has update afterthe close.
(VRTX) VErtex showed promise with Merck on its leukemia drug;also VRTX to be added to NASDAQ 100 Index on 12/18.
(ZION) Zions Bancorp announced a $400M share buyback plan.
Pre-Market Stock News (DEC 11, 2006)
Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.
McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.
His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.
A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.
TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.
McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.
Top Gaining Stocks
Top Losing Stocks